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Abstract:  The  α1A-adrenergic  receptor  (α1A-AR)  antagonist  is  useful  in  treating  
benign  prostatic  hyperplasia,  lower  urinary  tract  symptoms,  and  cardiac  arrhythmia.  
Three-dimensional  quantitative  structure-activity  relationship  (3D-QSAR)  studies  were 
performed  on  a  set  of  α1A-AR  antagonists  of  N-aryl  and  N-nitrogen  class.  Statistically 
significant models constructed from comparative molecular field analysis (CoMFA) and 
comparative molecular similarity indices analysis (CoMSIA) were established based on a 
training set of 32 ligands using pharmacophore-based molecular alignment. The leave-one-
out cross-validation correlation coefficients were q
2
CoMFA = 0.840 and q
2
CoMSIA = 0.840. 
The high correlation between the cross-validated/predicted and experimental activities of  
a  test  set  of  12  ligands  revealed  that  the  CoMFA  and  CoMSIA  models  were  robust 
(r
2
pred/CoMFA = 0.694; r
2
pred/CoMSIA = 0.671). The generated models suggested that electrostatic, 
hydrophobic, and hydrogen bonding interactions play important roles between ligands and 
receptors  in  the  active  site.  Our  study  serves  as  a  guide  for  further  experimental 
investigations on the synthesis of new compounds. Structural modifications based on the 
present 3D-QSAR results may lead to the discovery of other α1A-AR antagonists. 
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1. Introduction 
Adrenergic  receptors  are members of the  G-protein coupled receptor superfamily of membrane 
proteins that mediate effects of the sympathetic nervous system through the actions of epinephrine and 
norepinephrine and control the equilibrium of the cardiovascular system. The receptors have  been 
classified into three classes (α1, α2, and β) with three members in the α1 subfamily, namely, α1A, α1B, 
and α1D [1]. Many physiological processes, including smooth muscle contraction, myocardial inotropy 
and  chronotropy,  and  hepatic  glucose  metabolism  are  related  to  the  α1A-adrenergic  receptors  
(α1A-ARs); thus, clinical applications of these receptors are of interest to many scientists. The α1A-AR 
antagonists are considered as the first-line of therapy for lower urinary tract symptoms associated with 
clinical benign prostatic hyperplasia (BPH), because they have proven efficacy in mediating smooth 
muscle contraction in the human prostate [2]. 
Reports on the application of QSAR analysis to α1-AR species are relatively limited [3–6]. The 
SAR  of  39  α1  adrenoceptor  antagonists  derived  from  the  antipsychotic  sertindole  with  respect  to 
affinity  was  investigated  using  a  3D-QSAR  approach  based  on  the  GRID/GOLPE  methodology  
by  Balle’s  group  [7].  Montorsi  reported  quantitative  size  and  shape  affinity/subtype  selectivity 
relationships derived from a large set of very heterogeneous α1a-, α1b-, and α1d-adrenergic receptor 
antagonists  [8].  Maciejewska  et  al.  reported  a  structure-activity  analysis  of  hexahydro  and 
octahydropyrido-(1,2-c)-pyrimidine derivatives as α1A-AR antagonists, using comparative molecular 
field analysis (CoMFA) [9]. Li’s and Xia’s groups provided insights into α1A-adrenoceptor antagonists 
through  self-organizing  molecular  field  analysis  in  the  same  year  [10].  Shakya  et  al.  reported  
3D-QSAR  models  based  on  a  series  of  25  dihydropyridine  class  compounds  using  the  APEX-3D 
program, which can automatically identify biphore (pharmacophore) sites, and 3D-QSAR modeling [11]. 
Compared with SOMFA studies, the model has strong predictability, particularly for compounds with 
enantio-selectivity. Last year, Gupta reported on studies based on CoMFA and comparative molecular 
similarity indices analysis (CoMSIA) performed on a set of diverse α1A-AR antagonists to understand 
the relationship between structure and antagonistic activity [12]. This study was based on common 
structural  alignments.  The  generated  models  suggest  that  steric,  electrostatic,  and  hydrophobic 
interactions play important roles in structure-activity analysis.  
The superimposition of compounds in an alignment is crucial in 3D-QSAR studies. Many studies 
have reported that pharmacophore alignment is a useful tool that is superior to others [13,14]. Genetic 
algorithm with linear assignment of hypermolecular alignment of datasets (GALAHAD
®) is regarded 
as a superior tool for molecular alignment compared with classical common structural alignment [15], 
especially for compounds that share few structural commonalities. GALAHAD uses the proprietary 
technology of Tripos
® and generates pharmacophore alignments and hypotheses from sets of ligand 
molecules using a genetic algorithm [16]. The relationship between the chemical structures and the 
biological function studies based on the pharmacophore alignments of α1A-adrenergic receptor using Int. J. Mol. Sci. 2011, 12  7024 
 
 
GALAHAD has yet to be reported. Based on the alignment obtained, CoMFA and CoMSIA models 
were developed. The information derived from these models will be helpful in predicting the activity 
and guiding the design of other α1A-AR antagonists. 
2. Materials and Method 
2.1. Data Collection  
All α1A-AR antagonist structures were collected from recent reports (Figure 1 and Table 1) [17–25]. 
The selected compounds have diverse structural features and cover a wide range of biological activity, 
spanning over four orders of magnitude (0.1–630 nM). The training and test sets were classified to 
ensure that both sets could completely cover the whole range of biological activity and physicochemical 
and  structural  diversity  studied.  The  need  for  models  to  be  tested  on  a  sufficiently  large  test  set  
(25%–33% of the total samples) to establish a reliable QSAR model had been previously suggested [26]. 
Therefore,  the  dataset,  which  was  composed  of  44  compounds,  was  divided  into  training  (32 
compounds)  and  test  (12  compounds)  sets.  All  data  from  various  references  were  from  the  same 
laboratory. The affinity constants of compounds were evaluated by radio-receptor binding assays. [
3H] 
Prazosin was used to label cloned human α1-ARs expressed in CHO cells and WB4101 was used as a 
reference compound. Ki values were derived from IC50 using the Cheng-Prusoff equation [27]. All  
Ki values were expressed as pKi values (−log Ki). 
Figure 1. Structures of the α1A-AR antagonists used in the 3D-QSAR study. 
 
Table 1. Structures of the training set molecules used in the 3D-QSAR study. 
Series 
Compd. 
No.        R1  R2  R3  X  Ki(nM)  pKi 
I 
1  4-Cl  -OCH3  -OCH3  O  0.251  9.60 
2  2-CH3  -OCH3  -OCH3  O  1.58  8.80 
3  3-CH3  -OCH3  -OCH3  O  0.398  9.40 
4  4-CH3  -OCH3  -OCH3  O  1.99  8.70 
5  3-OCH3  -OCH3  -OCH3  O  1.99  8.70 
6  4-OCH3  -OCH3  -OCH3  O  1.99  8.70 
7  H  -OCH3  -OCH3  S  3.16  8.50 
8  H  -OC2H5  -OC2H5  O  3.16  8.50 
9  H  -OC2H5  -H  O  2.00  8.70 Int. J. Mol. Sci. 2011, 12  7025 
 
 
Table 1. Cont. 
Series 
Compd. 
No.  R1  R2  R3  X  Ki(nM)  pKi 
II 
10  -Cl  -  -  -  441.29  6.36 
11  -CH  -  -  -  467.33  6.33 
12  -CN  -  -  -  170.88  6.77 
13  -Br  -  -  -  301.13  6.52 
14  -F  -F  -  -  108.10  6.97 
15  -Cl  -CH3  -  -  100.44  7.00 
16  -CH3  -CH3  -  -  95.42  7.02 
17  -CH3  -Cl  -  -  152.20  6.82 
18  -CN  -Cl  -  -  402.56  6.39 
19  -Cl  -F  -  -  86.16  7.06 
III 
20 
S  
-OCH3  -OCH3  -  0.08  10.05 
21 
 
-OCH3  -OCH3  -  0.51  9.29 
22 
O   -OCH3  -OCH3  -  3.23  8.49 
IV 
23    2-Cl  5-Cl  -  95.68  7.02 
24    2-Cl  5-Cl  -  264.40  6.58 
25 
 
2-Cl  5-Cl  -  73.57  7.13 
26    2-OCH3  -  -  23.4  7.63 
27    2-OCH3  -  -  43.54  7.36 
28    2-Cl  5-Cl  -  21.77  7.66 
29 
O OH
  2-OCH3  -  -  5.88  8.23 
30  O
O
H
 
2-OCH3  -  -  7.94  8.10 
31 
O
O
H
  2-OCH3  -  -  28.84  7.54 
V  32  -  -  -  -  629.04  6.20 
2.2. Structural Sketch and Alignment 
Structural sketches and refinement of the entire set of α1A-AR antagonists were accomplished using 
SYBYL
®  8.1  molecular  modeling  software  (Tripos  Associates  Inc.)  and  their  3D  structures  were 
generated using CONCORD
®. All compounds were minimized under the Tripos standard (TS) force 
field [28] with Gasteiger-Hückel atomic partial charges [29]. Minimizations were done using the Powell 
method, in which calculations were set to terminate at an energy gradient value of 0.01 kcal/mol. 
Pharmacophore  results  for  N-Aryl  and  N-heteroaryl  piperazine  α1A-AR  antagonists  using 
GALAHAD have been reported previously [30], and the optimized model from the previous report 
was used as a template in the present study. All compounds in the training and test sets were aligned 
with this template using the “Align Molecules to Template Individually” option in GALAHAD. The 
other parameters for calculation were set to default values.  
N
O
O
N
O
O
N
O
O
N
O
N
O
N
OInt. J. Mol. Sci. 2011, 12  7026 
 
 
2.3. 3D-QSAR Studies 
CoMFA, a method that reflects the non-bonding interaction between the receptor and the ligand, is 
widely  used  in  drug  design.  The  steric  (Lennard-Jones)  and  electrostatic  (Coulombic)  potential 
energies  of  the  TS  force  fields  implemented  in  SYBYL  were  evaluated  by  CoMFA.  For  each 
pharmacophore alignment ligand, a 3D cubic lattice with a grid spacing of 1.0 Å in the x, y, and z 
directions was generated to enclose the molecule aggregate. A sp
3 carbon atom with a charge of +1.0 
and a Van der Waals radius of 1.52 Å was used as a probe; this atom was placed at every lattice point 
to calculate various steric and electrostatic fields. An energy cut off value of 30 kcal/mol was imposed 
on all CoMFA calculations to avoid excessively high and unrealistic energy values within the molecule. 
Then, partial least-squares (PLS) analysis was applied to obtain the final model [31]. 
During  calculation  of  the  steric  and  electrostatic  fields  in  CoMFA,  many  grid  points  on  the 
molecular surface were ignored due to the rapid increase in Van der Waals repulsion. To avoid a 
drastic change in the potential energy of the grid points near the molecular surface, CoMSIA employed 
a Gaussian-type function based on distance. Thus, CoMSIA may be capable of obtaining more stable 
models than CoMFA in 3D-QSAR studies [31–33]. The constructed CoMSIA model provided information 
on steric, electrostatic, hydrophobic, hydrogen bond donor, and hydrogen bond acceptor fields.  
The  grid  constructed  for  the  CoMFA  field  calculation  was  also  used  for  the  CoMSIA  field 
calculation [32]. Five physico-chemical properties (electrostatic, steric, hydrophobic, and hydrogen 
bond donor and acceptor) were evaluated using a common probe atom placed within a 3D grid. A 
probe atom sp
3 carbon with a charge, hydrophobic interaction, and hydrogen-bond donor and acceptor 
properties of +1.0 was placed at every grid point to measure the electrostatic, steric, hydrophobic, and 
hydrogen  bond  donor  or  acceptor  field.  Similar  to  CoMFA,  the  grid  was  extended  beyond  the 
molecular dimensions by 1.0 Å in three dimensions and the spacing between probe points within the grid 
was set to 1.0 Å. Different from the CoMFA, a Gaussian-type distance dependence of physicochemical 
properties (attenuation factor of 0.3) was assumed in the CoMSIA calculation. 
The  partial  least  squares  (PLS)  method  was  used  to  explore  a  linear  correlation  between  the 
CoMFA and CoMSIA fields and the biological activity values [34]. It was performed in two stages. 
First, cross-validation analysis was done to determine the number of components to be used. This was 
performed using the leave-one-out (LOO) method to obtain the optimum number of components and 
the corresponding cross-validation coefficient, q
2 [35]. The value of q
2 that resulted in a minimal 
number of components and the lowest cross-validated standard error of estimate (Scv) was accepted. 
The column filtering values (σmin) was set to 2.0 kcal/mol in order to speed up the analytical process 
and reduce noise. Second, the optimum number of components were used to derive the final PLS 
model, with no validation method [36,37]. The CoMFA and CoMSIA results were then graphically 
interpreted by field contribution maps. 
2.4. Predictive Power of the Models 
The predictive power of the 3D-QSAR model was determined from a set of 12 compounds in the 
test  set  (Table  2).  These  molecules  were  superimposed  using  the  same  pharmacophore  molecular 
alignment method described above, and their activities were predicted using the CoMFA and CoMSIA Int. J. Mol. Sci. 2011, 12  7027 
 
 
models generated by the training set. The predictive correlation coefficient, r
2
pred, of the CoMFA and 
CoMSIA models were calculated using the test set, according to the formula, 
SD-PRESS 2
SD
rpred =   (1)  
where SD is the sum of the squared deviations of each experimental value from the mean, and PRESS 
is  the  sum  of  the  squared  differences  between  the  predicted  and  actual  affinity  values  for  every 
molecule [31].  
Table 2. Structures of the test set molecules used in the 3D-QSAR study. 
Series 
Compd. 
No.       
R1  R2  R3  X  Ki(nM)  pKi 
I  33  2-Cl  -OCH3  -OCH3  O  1.41  8.85 
II 
34  -Br  -Br  -  -  91.25  7.04 
35  -Cl  -I  -  -  383.60  6.42 
III 
36 
O
O
 
-OCH3  -  -  27.54  7.57 
37 
 
-OCH3  -OCH3  -  2.34  8.63 
38 
O  
-OCH3  -OCH3  -  0.40  9.40 
39 
O
 
-OCH3  -OCH3  -  72.44  7.14 
IV 
40 
N
O
O  
-Cl  -Cl  -  2.28  8.64 
41 
N
O
O
N
 
-OCH3  -  -  235.52  6.63 
42 
N
O
O
 
-Cl  -Cl  -  47.86  7.32 
43  N
O
 
-Cl  -Cl  -  33.93  7.47 
V  44 
NH2
O
NH
F
F
F
N
O
O
 
31.62  7.50 
3. Results and Discussion 
3.1. Alignment 
The  pharmacophore  model  generated  by  GALAHAD  contained  one  donor  center,  one  positive 
charged nitrogen atom, two acceptor centers, and two hydrophobic centers, more than other reported 
models,  which  is  shown  in  [Figure  2(a)].  The  internal  distance  of  the  pharmacophore  feature  is 
consistent  with  previously  reported  models.  The  pharmacophore  model  has  reasonable  assessment 
parameters, such as a high specificity value (4.212), high steric score (4903.5), and low energy value 
(92.9 Kcal/mol) [30,38]. All of the compounds were superimposed based on the template [Figure 2(b)]. 
Ligands have the same binding site and share common interactions. However, they sometimes do not 
share  common  structures.  GALAHAD,  as  an  alignment  tool,  considers  the  flexibility  of  each Int. J. Mol. Sci. 2011, 12  7028 
 
 
compound and performs a compact alignment based on essential structural elements related to activity 
by variation of the torsional degrees of freedom. Compared to the QSAR model previously reported, 
the  classical  approach  based  on  a  rigid  alignment  of  minimized  structures,  does  not  show  any 
uniformity  with  the  active  conformation.  Pharmacophore-based  molecular  alignment  using 
GALAHAD in the current manuscript will generate a rational alignment for 3D-QSAR studies.  
Figure  2.  The  alignment  of  the  molecules  in  the  present  study  (b)  based  on  the 
pharmacophore hypothesis (a) using GALAHAD; magenta, hydrogen bond donor atom 
(D); green, acceptor atom (A); cyan, hydrophobic center (H); red, positive nitrogen (P). 
 
3.2. CoMFA and CoMSIA Models 
A statistically significant 3D-QSAR model was obtained using the properly selected training set of 
32 ligands. Results of the statistical analysis are presented in Table 3.  
In the CoMFA model, initial PLS analysis of the aligned training set was done using a default σmin 
data filter of 2.0 kcal/mol and the Tripos standard field. This yielded a highly significant q
2 value of 
0.840 (with Scv = 0.476, using four components), which indicates that it is a model with high statistical 
significance;  a  q
2  value  of  0.6  is  considered  statistically  significant  in  CoMFA  and  CoMSIA  
studies [39]. The conventional r
2 value of 0.988 and low standard error of estimate (SEE) value of 
0.128 indicate the accuracy of the predictions of the model. High values of q
2 from the LOO analysis 
can  be  regarded  as  a  necessary,  but  not  a  sufficient,  condition  for  a  model  to  possess  significant 
predictive power [40]. In addition to LOO, the internal predictive ability of the model was further 
assessed by a group cross-validation performed with 30 groups for 30 times. The mean of 30 readings 
was given as r
2
cv; the mean r
2
cv of 0.837 also suggests that the model has good internal predictability. 
Similar  to  CoMFA,  the  CoMSIA  model  with  the  steric,  electrostatic,  hydrophobic,  donor  and 
acceptor fields result in satisfactory statistical data (Table 3, model A). However, the steric and donor 
fields  (10%  and  18%  contribution,  respectively)  did  not  significantly  contribute  to  affinity  in  the  
all-fields model. Moreover, presumably correlated fields increase the complexity of contour maps and 
complicate their interpretation. Therefore, CoMSIA approaches with smaller subsets of fields were 
calculated (Table 3, columns B-E). The hydrophobic field was always considered in accordance with 
the  hydrophobic  groups  in  the  pharmacophore  model.  The  internal  predictivities  of  the  field 
combinations B-E were only slightly reduced compared to the all-fields model A. Among the five 
models, the combination of the electrostatic, hydrophobic, and acceptor field (model E) has the highest 
external predictivity (r
2
pred = 0.671). The conventional non-cross validated r
2 of 0.975 and the SEE Int. J. Mol. Sci. 2011, 12  7029 
 
 
value of 0.180 indicate that this model is statistically highly significant. Analogous to the CoMFA, a 
group cross-validation was done to assess further the internal predictive ability of the model. The 
cross-validation was performed 30 times with 30 groups. The mean r
2
cv obtained was 0.864, which 
also indicated the robustness of this model.  
Table 3. Statistical analysis of CoMFA and CoMSIA models  
Parameters 
a 
CoMFA  CoMSIA 
b 
  A  B  C  D  E 
Optimal PLS component  4  3  3  3  2  3 
q
2  0.840  0.874  0.866  0.842  0.856  0.840 
Scv  0.476  0.407  0.419  0.456  0.427  0.459 
r
2  0.988  0.980  0.982  0.977  0.961  0.975 
SEE  0.128  0.160  0.154  0.174  0.222  0.180 
F  555.64  469.24  510.31  394.83  357.74  370.67 
r
2
cv  0.837          0.864 
Fractions             
Steric  0.460  0.104  0.203  0.153  0.133   
Electrostatic  0.540  0.217  0.386  0.297  0.264  0.347 
Hydrophobic    0.212  0.410  0.336    0.399 
Donnor    0.183      0.360   
Acceptor    0.285    0.214  0.243  0.254 
r
2
pred  0.694  0.646  0.581  0.576  0.663  0.671 
a  q
2,  leave-one-out  cross-validation  correlation  coefficient;  Scv,  leave-one-out  cross-validated 
standard error; r
2, conventional correlation; SEE, standard error of estimate; F, F-test value; r
2
cv, 
conventional  correlation of  group  cross-validation; 
b  CoMSIA  model  calculated  using  different 
field  combinations.  A,  all  fields;  B,  Steric,  electrostatic  and  hydrophobic  fields;  C,  Steric, 
electrostatic hydrophobic and acceptor fields; D, Steric, electrostatic donor and acceptor fields;  
E, electrostatic hydrophobic and acceptor fields. 
3.3. Predictive Power of the Models 
The cross-validated pKi values calculated by CoMFA and CoMSIA, and the residuals between the 
experimental and cross-validated pKi values of the compounds in the training set are listed in Table 4. 
The predictive powers of the CoMFA and CoMSIA models were further examined using a test set of 
12 compounds not included in the training set. The predicted pKi values calculated by CoMFA and 
CoMSIA are also shown in Table 4.  
 Int. J. Mol. Sci. 2011, 12  7030 
 
 
Table  4.  Experimental  and  cross-validated/predicted  biological  affinities  and  residuals 
obtained by the CoMFA and CoMSIA (model E) for 32 compounds in the training set and 
12 compounds in the test set.
 
Compd. 
No. 
pKi (exp.)  pKi (pred.)  ∆pKi 
a 
CoMFA  CoMSIA  CoMFA  CoMSIA 
Training set 
1  9.60  9.620  9.561  −0.0197  0.0388 
2  8.80  8.743  8.896  0.0572  −0.0957 
3  9.40  9.410  9.273  −0.0103  0.1265 
4  8.70  8.593  8.680  0.1072  0.0201 
5  8.70  8.659  8.687  0.0412  0.0127 
6  8.70  8.649  8.777  0.0505  −0.0771 
7  8.50  8.510  8.611  −0.0103  −0.1113 
8  8.50  8.440  8.676  0.0602  −0.1755 
9  8.70  8.689  8.843  0.0108  −0.1432 
10  6.36  6.505  6.694  −0.1453  −0.3342 
11  6.33  6.385  6.474  −0.0548  −0.1435 
12  6.77  6.652  6.716  0.1176  0.0540 
13  6.52  6.559  6.605  −0.0385  −0.0847 
14  6.97  6.923  6.901  0.0472  0.0688 
15  7.00  7.113  7.035  −0.1129  −0.0352 
16  7.02  6.880  6.690  0.1404  0.3303 
17  6.82  6.793  6.656  0.0275  0.1644 
18  6.39  6.475  6.641  −0.0852  −0.2509 
19  7.06  7.011  7.024  0.0494  0.0363 
20  10.05  10.126  9.768  −0.0759  0.2821 
21  9.29  9.294  9.181  −0.0042  0.1095 
22  8.49  8.601  8.751  −0.1107  −0.2609 
23  7.02  6.871  6.661  0.1492  0.3588 
24  6.58  6.590  6.691  −0.0096  −0.1111 
25  7.13  7.177  7.202  −0.0472  −0.072 
26  7.63  7.653  7.404  −0.0229  0.2259 
27  7.36  7.365  7.290  −0.0055  0.0698 
28  7.66  7.697  7.423  −0.0371  0.2370 
29  8.23  8.275  8.179  −0.0451  0.0512 
30  8.10  8.070  8.265  0.0305  −0.1652 
31  7.54  7.576  7.631  −0.0364  −0.0906 
32  6.20  6.217  6.235  −0.0173  −0.0351 
Test set 
33  8.85  8.587  9.010  0.2629  −0.1603 
34  7.04  6.766  6.613  0.2737  0.4265 
35  6.42  6.669  6.653  −0.2490  −0.2334 
36  7.57  8.514  8.370  −0.9437  −0.800 
37  8.63  8.174  8.723  0.4563  −0.0931 
38  9.40  9.804  9.128  −0.4037  0.2719 Int. J. Mol. Sci. 2011, 12  7031 
 
 
Table 4. Cont. 
Compd. 
No. 
pKi (exp.)  pKi (pred.)  ∆pKi 
a 
CoMFA  CoMSIA  CoMFA  CoMSIA 
    Test set       
39  7.14  7.916  7.652  −0.7758  −0.5117 
40  8.64  7.996  7.506  0.6440  1.1341 
41  6.63  6.584  6.848  0.0461  −0.2182 
42  7.32  7.794  6.801  −0.4744  0.5191 
43  7.47  6.974  7.079  0.4955  0.3908 
44  7.50  7.341  7.852  0.1589  −0.3518 
r
2
pred 
b    0.694  0.671     
a ∆pKi is defined as pKi,experimental − pKi,cross-validated/predicted; 
b Predictive correlation coefficient of the 
test set is defined as r
2
pred = (SD – PRESS)/SD. 
The results show that the CoMFA model (r
2
pred = 0.694) gives a better prediction than the CoMSIA 
model does (r
2
pred = 0.671). Plots of the cross-validated/predicted pKi versus the experimental values 
are shown in Figure 3. The shaded diamonds and open squares represent the training set and the test set, 
respectively. 
Figure 3. Correlation between cross-validated/predicted pKi versus experimental pKi for 
the training set (shaded diamonds) and the test set (open squares); CoMFA graph (a) and 
CoMSIA graph (b). 
   
             (a)                            (b) 
3.4. Graphical Interpretation of the Fields 
The CoMFA and CoMSIA contour maps of the PLS regression coefficients at each region grid 
point  provide  a  graphical  visualization  of  the  various  field  contributions,  which  can  explain  the 
differences in the biological activities of each compound. These contour maps were generated using 
various field types of StDev*coefficients to show the favorable and unfavorable interactions between 
ligands and receptors in the active site. 
In  the  CoMFA  model,  the  fractions  of  steric  and  electrostatic  fields  are  46.0%  and  54.0%, 
respectively. Favorable and unfavorable cutoff energies were set at the 80th and 20th percentiles for 
the steric contributions. The contour maps of the fields are shown in [Figure 4(a)], with the higher Int. J. Mol. Sci. 2011, 12  7032 
 
 
affinity compound 20 as the reference structure. The surfaces indicate the regions where the increase 
(green region) or decrease (yellow region) in steric effect would be important for the improvement of 
binding  affinity.  The  large  green  isopleths  upon  the  thiochromene  part  reflect  a  sharp  increase  in 
affinity for all the anchor moieties transferred into this area. Compound 20, with its large bulky phenyl 
group, coincide with the green isopleths. When the thiochromene group in compound 20 was replaced 
by 8-methyl-8-azaspiro decane-7, 9-dione (such as compounds 24 and 32), and the yellow region was 
occupied  by  the  large  bulky  groups,  and  the  antagonistic  activity  of  these  compounds  evidently 
decreased. This was probably due to the insufficient space to accommodate these bulky groups in the 
anchor moieties ofthe receptor-binding site, which caused collision among groups and the reduced 
affinity of the compounds. [Figure 4(b)] shows the electrostatic contributions with compound 20 as a 
template ligand. The electrostatic contour map shows regions of red polyhedra (contribution level: 
15%), where electron-rich substituents are beneficial for the binding affinity, whereas the blue colored 
regions  (contribution  level:  85%)  show  the  areas  where  positively  charged  groups  enhance  the 
antagonistic  activity.  The  large  blue  area  near  the  thiochromane  moiety  indicates  a  region  where 
negatively charged groups decrease antagonistic activity. Compound 32 has a carbonyl in the blue area, 
which may be not conducive to the improvement of activity. The electrostatic contour map shows a 
region of red contours neighbor to the oxygens connects with benzene, indicating that electron-rich 
substituents (such as bromine, cyano group) are beneficial for the binding affinity. 
Figure 4. Steric (a) and electrostatic (b) contours with high-affinity compound 20 in the 
final CoMFA model; B, blue; G, green; R, red; Y, yellow. 
 
In the CoMSIA model, the fractions of the electrostatic, hydrophobic, and hydrogen-bond donor 
and acceptor fields were 34.7%, 39.9% and 25.4%, respectively. The CoMSIA contour plots are also 
exemplified by some ligands of high affinity. Similarly, red and blue isopleths (contribution levels: 
15% and 85%, respectively) of the electrostatic fields [Figure 5(a)] enclose regions, where negative 
and positive charges have favorable effects on pKi, respectively. The contour maps of electrostatic 
fields are similar to that of the CoMFA. Compared with the CoMFA model, its electronic field areas 
are smaller. The blue contours rather indicate where negatively charged substructures are unfavorable, 
such as methyl substitution and amino substitution should be placed to enhanced binding affinity, 
while the red contours neighboring to oxygens indicate electronegative groups will do a favorable 
effect of antagonistic potency. Int. J. Mol. Sci. 2011, 12  7033 
 
 
Figure 5. Contour plots illustrating, electrostatic (a), hydrophobic (b) and hydrogen bond 
acceptor (c) properties revealed by the CoMSIA model; high affinity compounds 20 shown 
as templates; B, blue; C, cyan; Gr, gray; M, magenta; O, orange; R, red. 
 
For hydrophobic field contributions, orange and gray isopleths are drawn at contribution levels of 
85% and 15%, respectively. These enclose regions favorable for hydrophobic and hydrophilic groups, 
respectively [Figure 5(b)]. Orange areas are mainly distributed in the thiochromene side, which is 
consistent with the hydrophobic center of the pharmacophore hypotheses, as well as with the contour 
maps of the steric fields generated by the CoMFA and CoMSIA models. Hydrophobic interactions 
may be dominant for ligand binding. These areas suggest the importance of hydrophobic interaction 
near  the  phenylchroman  group  of  the  most  active  compound  in  the  training  set.  Halogen  (except 
fluorine)  substitution  in  orange  region  will  enhance  molecular  hydrophobic  field  and  increase  the 
affinity of the compound. In addition, the introduction of hydrophilic groups (such as amide and amine) 
on the other side of the benzene ring (transparent gray) may increase α1A-AR antagonistic activity, 
whereas chlorine substitution in compound 32 may reduce the binding activity of α1A-AR, which is a 
representative of weak α1A-AR receptor binding. 
The  graphical  interpretation  of  the  field  contributions  of  the  H-bond  properties  is  shown  in  
[Figure  5(c)]  (the  H-bond  acceptor  field).  Magenta  isopleths  (80%)  encompass  regions  wherein 
hydrogen bond acceptor groups lead to improved α1A-AR antagonist activity; while areas encompassed 
by red isopleths (20%) should be avoided from hydrogen bond acceptor, which will result in impaired 
biological activity. Small red isopleths are inlaid in the purple region. The oxygen atom connected to 
the phenyl group may be an important factor to high activity of compound 20. The introduction of a 
hydrogen bond acceptor in the area may further improve the activity.  
3D structures of human α1A-AR homology models have been successfully developed by Li’s group 
based on the crystal structure of β2-AR [41]. This optimized homology model was retrieved from 
Protein Model Data Base (PMDB entry: PM0075211). The pharmacophore features were placed into 
the  binding  pocket  of  this  model,  as  shown  in  Figure  6.  According  to  previous  reports  [41,42], 
hydrophobic  interactions  may  occur  between  the  hydrophobic  group  of  a  ligand  and  pockets 
constituted by Trp102, Cys110, Tyr111, Ser158, Phe193, Phe288, Phe289 and Phe312. Asp106 seems 
to  play  a  role  in  antagonist  binding  through  strong  electrostatic  interactions  with  the  protonated 
nitrogen  atom. Ser188 and Ser192 may have H-bond effects with acceptor and donor features.  In 
contrast to the most reported 3D-QSAR models mentioned in “Introduction”, GALAHAD was used in 
the present models to superimpose ligands based on pharmacophore molecular alignment. The flexible 
superimposition afforded by the current models more closely coincides with the receptor binding sites Int. J. Mol. Sci. 2011, 12  7034 
 
 
and reduces the likelihood of confusion arising from compounds belonging to different classes. The 
generated models suggested that electrostatic, hydrophobic, and hydrogen bonding interactions play 
important roles between ligands and receptors in the active site. The q
2, r
2
pred and contours obtained 
from the present CoMFA and CoMSIA model show strong predictability and application and provide 
detailed  information  about  the  molecular  features  of  the  ligands,  which  will  contribute  to  the 
antagonistic potency.  
Figure 6. The binding pocket of α1A-AR homology model with compound 20 matching  
the pharmacophore. 
 
4. Conclusions 
CoMFA  and  CoMSIA  models  were  established  based  on  a  training  set  of  32  ligands  using 
pharmacophore-based molecular alignment by GALAHAD. The statistical significance of the models 
was evaluated. The q
2 values of the CoMFA and CoMSIA models are 0.840 (4 components) and 0.840 
(3  components),  respectively.  These  models  also  predict  the  biological  activities  of  12  ligands  of  
α1A-AR antagonists in the test set. 
In  this  study,  GALAHAD  is  a  useful  pharmacophore  alignment  tool  that  can  yield  a  good  
3D-QSAR  model  for  α1A-AR  antagonists.  The  present  results  of  the  3D-QSAR model  provided  a 
valuable tool for predicting the activities of novel α1A-AR antagonists and a basis upon which more 
active compounds can be derived by targeted structural modifications.  
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